Europe Fluorescent In Situ Hybridization Fish Market
Taille du marché en milliards USD
TCAC :
% 
 Période de prévision |
2024 –2030 |
 Taille du marché (année de référence) |
|
 Taille du marché (année de prévision) |
Dollars américains 474.68 |
 TCAC |
% |
| Principaux acteurs du marché |
>Marché européen de l'hybridation in situ fluorescente (FISH), par type de produit (consommables, instruments et logiciels), technologie (hybridation in situ fluorescente d'ADN, hybridation in situ fluorescente d'ARN, hybridation in situ fluorescente de PNA et autres), application (recherche sur le cancer, recherche génétique, maladies infectieuses , médecine personnalisée et autres), utilisation (clinique, recherche et diagnostic d'accompagnement), utilisateur final (hôpitaux et cliniques, laboratoires de diagnostic, sociétés pharmaceutiques et biotechnologiques, organismes de recherche sous contrat, instituts universitaires et de recherche, et autres), canal de distribution (ventes au détail, appels d'offres directs, ventes en ligne et autres) - Tendances et prévisions de l'industrie jusqu'en 2030.
Analyse et perspectives du marché européen de l'hybridation in situ fluorescente (FISH)
La sensibilisation croissante du public au cancer et aux troubles génétiques a accru la demande sur le marché. Les principaux acteurs du marché se concentrent sur le lancement et l'approbation de divers produits au cours de cette période cruciale. En outre, l'augmentation des procédures améliorées et avancées de FISH contribue également à la demande croissante du marché.
Le marché européen de l'hybridation in situ fluorescente (FISH) devrait croître au cours de la période de prévision de 2023 à 2030 en raison de l'augmentation du cancer et d'autres maladies chroniques. Le financement élevé des activités de recherche par le gouvernement et d'autres organismes devrait également stimuler la croissance du marché. Parallèlement à cela, les fabricants sont engagés dans des activités de R&D pour lancer de nouveaux produits sur le marché. Cependant, le coût élevé des techniques FISH dans la procédure de traitement devrait freiner la croissance du marché. La demande croissante de biomarqueurs spécifiques et de diverses sondes devrait offrir l'opportunité de croissance du marché pour améliorer le traitement. La demande croissante de soins de santé de meilleure qualité pour les troubles génétiques et l'adoption croissante de la médecine personnalisée devraient stimuler la croissance du marché. Cependant, les préoccupations éthiques associées à la technologie FISH et le manque de professionnels qualifiés et certifiés devraient remettre en cause la croissance du marché.
Data Bridge Market Research analyse que le marché européen de l'hybridation in situ fluorescente (FISH) devrait atteindre une valeur de 474,68 millions USD d'ici 2030, à un TCAC de 7,5 % au cours de la période de prévision. Le segment des types de produits représente le segment le plus important du marché en raison du nombre croissant de cancers du sein et de troubles génétiques chez les patients. Ce rapport de marché couvre également en profondeur l'analyse des prix, l'analyse des brevets et les avancées technologiques.
|
Rapport métrique |
Détails |
|
Période de prévision |
2023 à 2030 |
|
Année de base |
2022 |
|
Année historique |
2021 (personnalisable de 2015 à 2020) |
|
Unités quantitatives |
Chiffre d'affaires en millions USD et prix en USD |
|
Segments couverts |
By Product Type (Consumables, Instrument, and Software), Technology (DNA Fluorescent in Situ Hybridization, RNA Fluorescent in Situ Hybridization, PNA Fluorescent in Situ Hybridization, and Others), Application (Cancer Research, Genetic Research, Infectious Disease, Personalized Medicine, and Other), Usage (Clinical, Research, and Companion Diagnostic), End User (Hospitals & Clinics, Diagnostic Laboratories, Pharmaceuticals & Biotechnology Companies, Contract Research Organizations, Academic & Research Institutes, and Others), Distribution Channel (Retail Sales, Direct Tender, Online Sales, and Others) |
|
Countries Covered |
Germany, France, U.K., Italy, Russia, Spain, Netherlands, Switzerland, Norway, Poland, Sweden, Belgium, Turkey, Denmark, Finland, and rest of Europe |
|
Market Players Covered |
Thermo Fisher Scientific Inc., Bio-Techne, Abbott, Agilent Technologies, Inc., Merck KGaA, F. Hoffmann-La Roche Ltd, Abnova Corporation, BioDot, Biocare Medical, LLC, Abcam plc., Sysmex Asia Pacific Pte Ltd (a subsidiary of Sysmex Corporation), BIOZOL Diagnostics Vertrieb GmbH, Zytomed Systems GmbH, Genemed Biotechnologies, Inc., Bio SB, BioGenex, Excilone, MetaSystems, Kaneka Eurogentec S.A., BioCat GmbH, and Leica Biosystems Nussloch GmbH among others |
Market Definition
A molecular cytogenetic technique called Fluorescence in Situ Hybridization (FISH) enables the localization of a particular DNA sequence or an entire chromosome in a cell. It is used to diagnose genetic disorders, map genes, identify chromosomal anomalies, and may also be used to compare how the genes on different chromosomes in related species are organized. While performing FISH, the double helix structure is unwound and all probes connected to fluorescent molecules are bound to a particular sequence of sample DNA that can be seen under a fluorescence microscope.
FISH is frequently used for diagnostic purposes in oncology, preventative and reproductive health, and genomic and cell biology research. It is the industry-recognized method for finding infectious illnesses and chromosomal abnormalities. However, strict regulations and standards for the approval of FISH products and probes are expected to restrain the market growth.
Europe Fluorescent in Situ Hybridization (FISH) Market Dynamics
This section deals with the understanding of market drivers, advantages, opportunities, restraints, and challenges. All of this is discussed in detail below:
Drivers
- Growing Burden of Genetic Disorders as Well as Cancer
Genetic abnormalities are uncommon as a whole but are very frequent as individual ailments. Gene changes are the cause of all cancer. Just 5% to 10% of cancers are genetically predisposed. Nevertheless, when the same cancer types run in families, heredity may occasionally seem to be the cause of cancer. Hematologic and solid cancers are both heterogeneous diseases with various genetic abnormalities. An increasing number of genomic abnormalities such as gain, loss, or rearrangement of chromosomal fragments and gene mutations, are driving factors in the pathogenesis of various malignancies as a result of the extensive investigations into the relationship between genomic instability and disease pathogenesis conducted over the last two decades. The clinical diagnosis of different chromosomal abnormalities, including deletions, duplications, and translocations, depends on FISH and other in situ hybridization techniques, which drives market growth.
- Innovation and Advancements in FISH Products
The most reliable method for finding specific DNA sequences, diagnosing genetic illnesses, mapping genes, and discovering new oncogenes or genetic abnormalities causing various cancers is FISH. Recent advancements in the technology have made it possible to screen the entire genome concurrently utilizing array-based methods such as comparative genomic hybridization or multiplex FISH with multicolor whole chromosome probes. In the fight against genetic diseases, FISH has fundamentally transformed the field of cytogenetics and is now acknowledged as a trustworthy diagnostic and research tool, which drives market growth.
Restraint
- High Cost of FISH Testing
The macromolecule recognition technique known as FISH relies on the complementary nature of DNA or DNA/RNA double strands. The FISH test "maps" the genetic material present in human cells, including particular genes or gene segments. A FISH test is helpful for diagnosing some types of cancer because it can find genetic abnormalities linked to the disease. Cost issues are of utmost relevance in the modern molecular diagnostic laboratory. In addition to enabling a laboratory to handle increased test volumes and throughput, automation of complicated molecular assays also significantly reduces the cost of testing from the standpoint of reagent expenses, which restrains market growth.
Opportunity
- Rising Public Awareness about the Early Detection of Genetic Abnormalities
Genetic testing aids patients in making important decisions in the prevention, treatment, or early detection of hereditary disorders. Low awareness of the importance of genetic testing contributes to the increase in the incidence of hereditary disorders.
A genetic disorder is a health condition that is inherited by a person, usually caused by mutations in the DNA or changes in the number or overall structure of chromosomes. Several types of commonly known diseases have been determined to be related to hereditary gene mutations.
Henceforth, the rising awareness about the early detection of genetic disorders using the FISH technique helps in the diagnosis of genetic diseases, gene mapping, and identification of novel oncogenes or genetic aberrations contributing to various types of cancers and genetic disorders, which provides the opportunity for market growth.
Challenge
- Stringent Government Regulations for the Approval of FISH Probes
The use of FISH techniques across the globe is rapidly increasing, with the growth of the aged population and several chronic diseases, which are preventable by early diagnosis and timely treatments. At the same time, the players of the FISH technology in the market have to follow certain regulations to get approval from the upper authorities for launching the product in a region. These stringent guidelines need to be followed, and this is one of the most difficult tasks of all the steps. The pre-market approval of various medical devices varies from one country to another.
Post-COVID-19 Impact on Europe Fluorescent in Situ Hybridization (FISH) Market
The pandemic has had adverse impacts on the FISH manufacturers as well as users. The market has been significantly influenced by COVID-19, which has led to an increase in research studies utilizing FISH. One such study, published in November 2022 in the PLOS One Journal, employed a FISH-based method to detect SARS-CoV-2 in saliva. The method involved using a Cy3-labeled DNA probe specific to SARS-CoV-2, and the analysis was carried out manually using fluorescence microscopy as a proof-of-concept.
Manufacturers are making various strategic decisions to bounce back post-COVID-19. The players are conducting multiple R&D activities, product launches, and strategic partnerships to improve the technology and test results involved in the FISH market.
Recent Developments
- In March 2023, Abcam plc. announced that it has received "Antibody Supplier of the Year" in CiteAb's distinguished annual industry awards. This comes after Fast Company recently listed Abcam plc. as one of the most innovative companies in the world for its ground-breaking efforts to increase data reproducibility. The provider with the most antibody product citations in 2022 receives CiteAb's "Antibody Supplier of the Year" honor. Moreover, Abcam plc. was given a "highly commended" rating in the category of "Post Translational Modification Antibody Supplier of the Year," recognizing the difficulty in creating and validating antibodies for these challenging targets. This has aided the business in becoming known on a Europe scale
- In March 2023, BIOZOL Diagnostics Vertrieb GmbH announced the acquisition of AlphaScience GmbH. By making this acquisition, BIOZOL Diagnostics Vertrieb GmbH strengthened its dominant position in the Europe market for research and diagnostics. With a significant number of new supplier connections, outstanding product knowledge, and staff who are well-trained technically, AlphaScience enhances BIOZOL. Significant synergy effects between the two organizations improving their offerings to customers and suppliers
- In July 2022, Bio-Techne announced the launch of the CE-IVD designated RNAscope ISH Probe High Risk HPV in Europe in order to help patients with Oropharyngeal Squamous Cell Carcinoma (OPSCC) identify high-risk Human Papillomavirus (HPV). For the qualitative identification of HPV E6/E7 mRNA in FFPE tissue samples, the RNAscope ISH Probe High Risk HPV is used. This has aided the business in offering better solutions all over the world
Europe Fluorescent in Situ Hybridization (FISH) Market Scope
The Europe Fluorescent in Situ Hybridization (FISH) market is segmented into six notable segments based on product type, technology, application, usage, end user, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
BY PRODUCT TYPE
- CONSUMABLES
- INSTRUMENT
- SOFTWARE
Based on product type, the market is segmented into consumables, instrument, and software.
BY TECHNOLOGY
- DNA FLUORESCENT IN SITU HYBRIDIZATION
- RNA FLUORESCENT IN SITU HYBRIDIZATION
- PNA FLUORESCENT IN SITU HYBRIDIZATION
- OTHERS
Based on technology, the market is segmented into DNA fluorescent in situ hybridization, RNA fluorescent in situ hybridization, PNA fluorescent in situ hybridization, and others.
BY APPLICATION
- CANCER RESEARCH
- GENETIC RESEARCH
- INFECTIOUS DISEASE
- PERSONALIZED MEDICINE
- OTHER
Based on application, the market is segmented into cancer research, genetic research, infectious disease, personalized medicine, and other.
BY USAGE
- CLINICAL
- RESEARCH
- COMPANION DIAGNOSTIC
Based on usage, the market is segmented into clinical, research, and companion diagnostic.
BY END USER
- HOSPITALS & CLINICS
- DIAGNOSTIC LABORATORIES
- PHARMACEUTICALS & BIOTECHNOLOGY COMPANIES
- CONTRACT RESEARCH ORGANISATIONS
- ACADEMIC & RESEARCH ORGANISATIONS
- OTHERS
Based on end user, the market is segmented into hospitals & clinics, diagnostic laboratories, pharmaceuticals & biotechnology companies, contract research organizations, academic & research institutes, and others.
BY DISTRIBUTION CHANNEL
- RETAIL SALES
- DIRECT TENDER
- ONLINE SALES
- OTHERS
Based on distribution channel, the market is segmented into direct tender, retail sales, online sales, and others.
Europe Fluorescent in Situ Hybridization (FISH) Market Regional Analysis/Insights
Le marché européen de l’hybridation fluorescente in situ (FISH) est analysé et des informations sur la taille du marché sont fournies en fonction du type de produit, de la technologie, de l’application, de l’utilisation, de l’utilisateur final et du canal de distribution.
Les pays couverts dans ce rapport de marché sont l'Allemagne, la France, le Royaume-Uni, l'Italie, la Russie, l'Espagne, les Pays-Bas, la Suisse, la Norvège, la Pologne, la Suède, la Belgique, la Turquie, le Danemark, la Finlande et le reste de l'Europe.
L'Allemagne devrait dominer la région Europe en raison de la production de masse de consommables et de kits de traitement FISH, de la demande croissante des marchés émergents et de l'expansion des industries de traitement des maladies veineuses.
La section par pays du rapport fournit également des facteurs individuels ayant un impact sur le marché et des changements dans la réglementation sur le marché national qui ont un impact sur les tendances actuelles et futures du marché. Des points de données tels que les nouvelles ventes, les ventes de remplacement, la démographie du pays, les actes réglementaires et les tarifs douaniers d'import-export sont quelques-uns des principaux indicateurs utilisés pour prévoir le scénario du marché pour les différents pays. En outre, la présence et la disponibilité des marques européennes et les défis auxquels elles sont confrontées en raison de la concurrence importante ou rare des marques locales et nationales, ainsi que l'impact des canaux de vente sont pris en compte lors de l'analyse prévisionnelle des données nationales.
Analyse du paysage concurrentiel et des parts de marché de l'hybridation in situ fluorescente (FISH) en Europe
Le paysage concurrentiel du marché européen de l'hybridation in situ fluorescente (FISH) fournit des détails sur les concurrents. Les détails inclus sont la présentation de l'entreprise, les finances de l'entreprise, les revenus générés, le potentiel du marché, les investissements en R&D, les nouvelles initiatives du marché, les sites et installations de production, les forces et les faiblesses de l'entreprise, le lancement du produit, les pipelines d'essais de produits, les approbations de produits, les brevets, la largeur et l'ampleur du produit, la domination des applications et la courbe de survie technologique. Les points de données ci-dessus fournis ne concernent que l'orientation de l'entreprise sur le marché.
Français Certains des principaux acteurs du marché opérant sur le marché européen de l'hybridation in situ fluorescente (FISH) sont Thermo Fisher Scientific Inc., Bio-Techne, Abbott, Agilent Technologies, Inc., Merck KGaA, F. Hoffmann-La Roche Ltd, Abnova Corporation, BioDot, Biocare Medical, LLC, Abcam plc., Sysmex Asia Pacific Pte Ltd (une filiale de Sysmex Corporation), BIOZOL Diagnostics Vertrieb GmbH, Zytomed Systems GmbH, Genemed Biotechnologies, Inc., Bio SB, BioGenex, Excilone, MetaSystems, Kaneka Eurogentec SA, BioCat GmbH et Leica Biosystems Nussloch GmbH, entre autres.
SKU-
Accédez en ligne au rapport sur le premier cloud mondial de veille économique
- Tableau de bord d'analyse de données interactif
- Tableau de bord d'analyse d'entreprise pour les opportunités à fort potentiel de croissance
- Accès d'analyste de recherche pour la personnalisation et les requêtes
- Analyse de la concurrence avec tableau de bord interactif
- Dernières actualités, mises à jour et analyse des tendances
- Exploitez la puissance de l'analyse comparative pour un suivi complet de la concurrence
Table des matières
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 MARKET APPLICATION COVERAGE GRID
2.8 PRODUCT LIFELINE CURVE
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PORTER’S FIVE FORCES
4.2 PESTEL ANALYSIS
4.3 INDUSTRY INSIGHTS
4.4 CONCLUSION
5 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: REGULATORY FRAMEWORK
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 GROWING BURDEN OF GENETIC DISORDERS AS WELL AS CANCER
6.1.2 INNOVATION AND ADVANCEMENTS IN FISH PRODUCTS
6.1.3 HIGH FUNDING FOR RESEARCH ACTIVITIES
6.1.4 RISING DEMAND AND USAGE OF FISH TECHNIQUES
6.2 RESTRAINTS
6.2.1 HIGH COST OF FISH TESTING
6.2.2 LIMITED AVAILABILITY OF SKILLED PROFESSIONALS
6.3 OPPORTUNITIES
6.3.1 RISING PUBLIC AWARENESS ABOUT THE EARLY DETECTION OF GENETIC ABNORMALITIES
6.3.2 RISE IN DEVELOPMENT OF SPECIFIC BIOMARKERS AND VARIOUS PROBES
6.4 CHALLENGES
6.4.1 STRINGENT GOVERNMENT REGULATIONS FOR THE APPROVAL OF FISH PROBES
6.4.2 ETHICAL CONCERNS ASSOCIATED WITH FISH TECHNOLOGY
7 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE
7.1 OVERVIEW
7.2 CONSUMABLES
7.2.1 FISH PROBE
7.2.1.1 FISH PROBE, BY PROBE TYPE
7.2.1.1.1 CHROMOSOME FISH PROBE
7.2.1.1.2 SPLIT FISH PROBES
7.2.1.1.3 TRANSLOCATION FISH PROBES
7.2.1.1.4 SUBTELOMERE FISH PROBES
7.2.1.1.5 PRENATAL FISH PROBES
7.2.1.1.6 OTHERS PROBES
7.2.1.2 FISH PROBE, BY TECHNOLOGY
7.2.1.2.1 FLOW FLUORESCENT IN SITU HYBRIDIZATION
7.2.1.2.2 C-ISH
7.2.1.2.3 D-ISH
7.2.1.2.4 Q- FLUORESCENT IN SITU HYBRIDIZATION
7.2.1.2.5 OTHERS
7.2.1.3 FISH PROBE, BY TYPE
7.2.1.3.1 RNA
7.2.1.3.1.1 MRNA
7.2.1.3.1.2 MIRNA
7.2.1.3.1.3 OTHERS
7.2.1.3.2 DNA
7.2.2 ACCESSORY KITS & REAGENTS
7.2.2.1 KITS
7.2.2.2 BUFFER
7.2.2.3 DYES
7.2.2.4 OTHERS
7.3 INSTRUMENT
7.3.1 STANDALONE
7.3.2 PORTABLE
7.3.3 HANDHELD
7.4 SOFTWARE
8 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TECHNOLOGY
8.1 OVERVIEW
8.2 RNA FLUORESCENT IN SITU HYBRIDIZATION
8.3 DNA FLUORESCENT IN SITU HYBRIDIZATION
8.4 PNA FLUORESCENT IN SITU HYBRIDIZATION
8.5 OTHERS
9 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION
9.1 OVERVIEW
9.2 CANCER RESEARCH
9.2.1 CANCER RESEARCH, BY CANCER TYPE
9.2.1.1 NON-HEMATOPOETIC MALIGNANCIES (SOLID TUMORS)
9.2.1.1.1 BREAST CANCER
9.2.1.1.2 LUNG CANCER
9.2.1.1.3 MELANOMA
9.2.1.1.4 PROSTRATE CANCER
9.2.1.1.5 OVARIAN CANCER
9.2.1.1.6 OTHERS
9.2.1.2 HEMATOPOETIC MALIGNANCIES
9.2.1.2.1 LEUKEMIA
9.2.1.2.2 MULTIPLE MYELOMA
9.2.1.2.3 MYELODYSPLASTIC SYNDROMES (MDS)
9.2.2 CANCER RESEARCH, BY PRODUCT
9.2.2.1 CONSUMABLES
9.2.2.2 INSTRUMENTS
9.2.2.3 SOFTWARE
9.3 GENETIC RESEARCH
9.3.1 CYTOGENETICS
9.3.2 CHROMOSOMAL ABNORMALITIES
9.3.3 OTHERS
9.4 INFECTIOUS DISEASE
9.4.1 CONSUMABLES
9.4.2 INSTRUMENTS
9.4.3 SOFTWARE
9.5 PERSONALIZED MEDICINE
9.6 OTHERS
10 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE
10.1 OVERVIEW
10.2 RESEARCH
10.2.1 INSTRUMENTS
10.2.2 CONSUMABLES
10.2.3 SOFTWARE
10.3 CLINICAL
10.3.1 CONSUMABLES
10.3.2 INSTRUMENT
10.3.3 SOFTWARE
10.4 COMPANION DIAGNOSTIC
10.4.1 CONSUMABLES
10.4.2 INSTRUMENT
10.4.3 SOFTWARE
11 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY END USER
11.1 OVERVIEW
11.2 DIAGNOSTIC LABORATORIES
11.3 HOSPITALS & CLINICS
11.4 PHARMACEUTICALS & BIOTECHNOLOGICAL COMPANIES
11.5 ACADEMIC & RESEARCH INSTITUTES
11.6 CONTRACT RESEARCH ORGANIZATIONS
11.7 OTHERS
12 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY DISTRIBUTION CHANNEL
12.1 OVERVIEW
12.2 RETAIL SALES
12.3 ONLINE SALES
12.4 DIRECT TENDER
12.5 OTHERS
13 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION
13.1 EUROPE
13.1.1 GERMANY
13.1.2 U.K.
13.1.3 ITALY
13.1.4 FRANCE
13.1.5 SPAIN
13.1.6 RUSSIA
13.1.7 SWITZERLAND
13.1.8 TURKEY
13.1.9 BELGIUM
13.1.10 NETHERLANDS
13.1.11 DENMARK
13.1.12 SWEDEN
13.1.13 POLAND
13.1.14 NORWAY
13.1.15 FINLAND
13.1.16 REST OF EUROPE
14 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, COMPANY LANDSCAPE
14.1 COMPANY SHARE ANALYSIS: EUROPE
15 SWOT ANALYSIS
16 COMPANY PROFILE
16.1 MERCK KGAA
16.1.1 COMPANY SNAPSHOT
16.1.2 REVENUE ANALYSIS
16.1.3 COMPANY SHARE ANALYSIS
16.1.4 PRODUCT PORTFOLIO
16.1.5 RECENT DEVELOPMENT
16.2 ABBOTT
16.2.1 COMPANY SNAPSHOT
16.2.2 REVENUE ANALYSIS
16.2.3 COMPANY SHARE ANALYSIS
16.2.4 PRODUCT PORTFOLIO
16.2.5 RECENT DEVELOPMENT
16.3 AGILENT TECHNOLOGIES, INC.
16.3.1 COMPANY SNAPSHOT
16.3.2 REVENUE ANALYSIS
16.3.3 COMPANY SHARE ANALYSIS
16.3.4 PRODUCT PORTFOLIO
16.3.5 RECENT DEVELOPMENT
16.4 F. HOFFMANN-LA ROCHE LTD.
16.4.1 COMPANY SNAPSHOT
16.4.2 REVENUE ANALYSIS
16.4.3 COMPANY SHARE ANALYSIS
16.4.4 PRODUCT PORTFOLIO
16.4.5 RECENT DEVELOPMENT
16.5 THERMO FISCHER SCIENTIFIC INC.
16.5.1 COMPANY SNAPSHOT
16.5.2 REVENUE ANALYSIS
16.5.3 COMPANY SHARE ANALYSIS
16.5.4 PRODUCT PORTFOLIO
16.5.5 RECENT DEVELOPMENT
16.6 ABCAM PLC.
16.6.1 COMPANY SNAPSHOT
16.6.2 REVENUE ANALYSIS
16.6.3 COMPANY SHARE ANALYSIS
16.6.4 PRODUCT PORTFOLIO
16.6.5 RECENT DEVELOPMENTS
16.7 ABNOVA CORPORATION
16.7.1 COMPANY SNAPSHOT
16.7.2 PRODUCT PORTFOLIO
16.7.3 RECENT DEVELOPMENT
16.8 BIO SB
16.8.1 COMPANY SNAPSHOT
16.8.2 PRODUCT PORTFOLIO
16.8.3 RECENT DEVELOPMENT
16.9 BIOCARE MEDICAL, LLC
16.9.1 COMPANY SNAPSHOT
16.9.2 PRODUCT PORTFOLIO
16.9.3 RECENT DEVELOPMENT
16.1 BIOCAT GMBH
16.10.1 COMPANY SNAPSHOT
16.10.2 PRODUCT PORTFOLIO
16.10.3 RECENT DEVELOPMENT
16.11 BIODOT
16.11.1 COMPANY SNAPSHOT
16.11.2 PRODUCT PORTFOLIO
16.11.3 RECENT DEVELOPMENT
16.12 BIOGENEX
16.12.1 COMPANY SNAPSHOT
16.12.2 PRODUCT PORTFOLIO
16.12.3 RECENT DEVELOPMENT
16.13 BIO-TECHNE
16.13.1 COMPANY SNAPSHOT
16.13.2 REVENUE ANALYSIS
16.13.3 COMPANY SHARE ANALYSIS
16.13.4 PRODUCT PORTFOLIO
16.13.5 RECENT DEVELOPMENT
16.14 BIOZOL DIAGNOSTICS VERTRIEB GMBH
16.14.1 COMPANY SNAPSHOT
16.14.2 PRODUCT PORTFOLIO
16.14.3 RECENT DEVELOPMENT
16.15 EXCILONE
16.15.1 COMPANY SNAPSHOT
16.15.2 PRODUCT PORTFOLIO
16.15.3 RECENT DEVELOPMENT
16.16 GENEMED BIOTECHNOLOGIES, INC.
16.16.1 COMPANY SNAPSHOT
16.16.2 PRODUCT PORTFOLIO
16.16.3 RECENT DEVELOPMENT
16.17 KANEKA EUROGENTEC S.A.
16.17.1 COMPANY SNAPSHOT
16.17.2 PRODUCT PORTFOLIO
16.17.3 RECENT DEVELOPMENT
16.18 LEICA BIOSYSTEMS NUSSLOCH GMBH
16.18.1 COMPANY SNAPSHOT
16.18.2 PRODUCT PORTFOLIO
16.18.3 RECENT DEVELOPMENT
16.19 METASYSTEMS
16.19.1 COMPANY SNAPSHOT
16.19.2 PRODUCT PORTFOLIO
16.19.3 RECENT DEVELOPMENT
16.2 SYSMEX ASIA PACIFIC PTE LTD (A SUBSIDIARY OF SYSMEX CORPORATION)
16.20.1 COMPANY SNAPSHOT
16.20.2 REVENUE ANALYSIS
16.20.3 PRODUCT PORTFOLIO
16.20.4 RECENT DEVELOPMENT
16.21 ZYTOMED SYSTEMS GMBH
16.21.1 COMPANY SNAPSHOT
16.21.2 PRODUCT PORTFOLIO
16.21.3 RECENT DEVELOPMENT
17 QUESTIONNAIRE
18 RELATED REPORTS
Liste des tableaux
TABLE 1 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 2 EUROPE CONSUMABLES IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 3 EUROPE CONSUMABLES IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 4 EUROPE FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PROBE TYPE, 2021-2030 (USD MILLION)
TABLE 5 EUROPE FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 6 EUROPE FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 7 EUROPE RNA IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 8 EUROPE ACCESSORY KITS & REAGENTS IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 9 EUROPE INSTRUMENT IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 10 EUROPE INSTRUMENTS IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 11 EUROPE SOFTWARE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 12 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 13 EUROPE RNA FLUORESCENT IN SITU HYBRIDIZATION IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 14 EUROPE DNA FLUORESCENT IN SITU HYBRIDIZATION IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 15 EUROPE PNA FLUORESCENT IN SITU HYBRIDIZATION IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 16 EUROPE OTHERS IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 17 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 18 EUROPE CANCER RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 19 EUROPE CANCER RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 20 EUROPE NON-HEMATOPOETIC MALIGNANCIES (SOLID TUMORS) IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 21 EUROPE HEMATOPOETIC MALIGNANCIES IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 22 EUROPE CANCER RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 23 EUROPE GENETIC RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 24 EUROPE GENETIC RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 25 EUROPE INFECTIOUS DISEASE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 26 EUROPE INFECTIOUS DISEASE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 27 EUROPE PERSONALIZED MEDICINE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 28 EUROPE OTHERS IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 29 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 30 EUROPE RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 31 EUROPE RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 32 EUROPE CLINICAL IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 33 EUROPE CLINICAL IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 34 EUROPE COMPANION DIAGNOSTIC IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 35 EUROPE COMPANION DIAGNOSTIC IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 36 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 37 EUROPE DIAGNOSTIC LABORATORIES IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 38 EUROPE HOSPITALS & CLINICS IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 39 EUROPE PHARMACEUTICAL & BIOTECHNOLOGICAL COMPANIES IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 40 EUROPE ACADEMIC & RESEARCH INSTITUTES IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 41 EUROPE CONTRACT RESEARCH ORGANIZATIONS IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 42 EUROPE OTHERS IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 43 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 44 EUROPE RETAIL SALES IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 45 EUROPE ONLINE SALES IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 46 EUROPE DIRECT TENDER IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 47 EUROPE OTHERS IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 48 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY COUNTRY, 2021-2030 (USD MILLION)
TABLE 49 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 50 EUROPE CONSUMABLES IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 51 EUROPE FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PROBE TYPE, 2021-2030 (USD MILLION)
TABLE 52 EUROPE FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 53 EUROPE FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 54 EUROPE RNA IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 55 EUROPE ACCESSORY KITS & REAGENTS IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 56 EUROPE INSTRUMENTS IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 57 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 58 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 59 EUROPE CANCER RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 60 EUROPE NON-HEMATOPOIETIC MALIGNANCIES (SOLID TUMORS) IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 61 EUROPE HEMATOPOIETIC MALIGNANCIES IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 62 EUROPE CANCER RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 63 EUROPE GENETIC RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 64 EUROPE INFECTIOUS DISEASE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 65 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 66 EUROPE RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 67 EUROPE CLINICAL IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 68 EUROPE COMPANION DIAGNOSTIC IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 69 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 70 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 71 GERMANY FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 72 GERMANY CONSUMABLES IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 73 GERMANY FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PROBE TYPE, 2021-2030 (USD MILLION)
TABLE 74 GERMANY FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 75 GERMANY FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 76 GERMANY RNA IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 77 GERMANY ACCESSORY KITS & REAGENTS IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 78 GERMANY INSTRUMENTS IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 79 GERMANY FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 80 GERMANY FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 81 GERMANY CANCER RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 82 GERMANY NON-HEMATOPOIETIC MALIGNANCIES (SOLID TUMORS) IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 83 GERMANY HEMATOPOIETIC MALIGNANCIES IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 84 GERMANY CANCER RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 85 GERMANY GENETIC RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 86 GERMANY INFECTIOUS DISEASE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 87 GERMANY FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 88 GERMANY RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 89 GERMANY CLINICAL IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 90 GERMANY COMPANION DIAGNOSTIC IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 91 GERMANY FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 92 GERMANY FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 93 U.K. FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 94 U.K. CONSUMABLES IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 95 U.K. FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PROBE TYPE, 2021-2030 (USD MILLION)
TABLE 96 U.K. FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 97 U.K. FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 98 U.K. RNA IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 99 U.K. ACCESSORY KITS & REAGENTS IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 100 U.K. INSTRUMENTS IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 101 U.K. FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 102 U.K. FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 103 U.K. CANCER RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 104 U.K. NON-HEMATOPOIETIC MALIGNANCIES (SOLID TUMORS) IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 105 U.K. HEMATOPOIETIC MALIGNANCIES IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 106 U.K. CANCER RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 107 U.K. GENETIC RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 108 U.K. INFECTIOUS DISEASE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 109 U.K. FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 110 U.K. RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 111 U.K. CLINICAL IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 112 U.K. COMPANION DIAGNOSTIC IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 113 U.K. FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 114 U.K. FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 115 ITALY FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 116 ITALY CONSUMABLES IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 117 ITALY FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PROBE TYPE, 2021-2030 (USD MILLION)
TABLE 118 ITALY FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 119 ITALY FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 120 ITALY RNA IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 121 ITALY ACCESSORY KITS & REAGENTS IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 122 ITALY INSTRUMENTS IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 123 ITALY FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 124 ITALY FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 125 ITALY CANCER RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 126 ITALY NON-HEMATOPOIETIC MALIGNANCIES (SOLID TUMORS) IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 127 ITALY HEMATOPOIETIC MALIGNANCIES IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 128 ITALY CANCER RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 129 ITALY GENETIC RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 130 ITALY INFECTIOUS DISEASE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 131 ITALY FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 132 ITALY RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 133 ITALY CLINICAL IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 134 ITALY COMPANION DIAGNOSTIC IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 135 ITALY FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 136 ITALY FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 137 FRANCE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 138 FRANCE CONSUMABLES IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 139 FRANCE FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PROBE TYPE, 2021-2030 (USD MILLION)
TABLE 140 FRANCE FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 141 FRANCE FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 142 FRANCE RNA IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 143 FRANCE ACCESSORY KITS & REAGENTS IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 144 FRANCE INSTRUMENTS IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 145 FRANCE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 146 FRANCE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 147 FRANCE CANCER RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 148 FRANCE NON-HEMATOPOIETIC MALIGNANCIES (SOLID TUMORS) IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 149 FRANCE HEMATOPOIETIC MALIGNANCIES IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 150 FRANCE CANCER RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 151 FRANCE GENETIC RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 152 FRANCE INFECTIOUS DISEASE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 153 FRANCE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 154 FRANCE RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 155 FRANCE CLINICAL IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 156 FRANCE COMPANION DIAGNOSTIC IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 157 FRANCE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 158 FRANCE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 159 SPAIN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 160 SPAIN CONSUMABLES IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 161 SPAIN FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PROBE TYPE, 2021-2030 (USD MILLION)
TABLE 162 SPAIN FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 163 SPAIN FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 164 SPAIN RNA IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 165 SPAIN ACCESSORY KITS & REAGENTS IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 166 SPAIN INSTRUMENTS IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 167 SPAIN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 168 SPAIN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 169 SPAIN CANCER RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 170 SPAIN NON-HEMATOPOIETIC MALIGNANCIES (SOLID TUMORS) IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 171 SPAIN HEMATOPOIETIC MALIGNANCIES IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 172 SPAIN CANCER RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 173 SPAIN GENETIC RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 174 SPAIN INFECTIOUS DISEASE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 175 SPAIN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 176 SPAIN RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 177 SPAIN CLINICAL IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 178 SPAIN COMPANION DIAGNOSTIC IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 179 SPAIN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 180 SPAIN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 181 RUSSIA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 182 RUSSIA CONSUMABLES IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 183 RUSSIA FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PROBE TYPE, 2021-2030 (USD MILLION)
TABLE 184 RUSSIA FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 185 RUSSIA FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 186 RUSSIA RNA IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 187 RUSSIA ACCESSORY KITS & REAGENTS IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 188 RUSSIA INSTRUMENTS IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 189 RUSSIA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 190 RUSSIA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 191 RUSSIA CANCER RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 192 RUSSIA NON-HEMATOPOIETIC MALIGNANCIES (SOLID TUMORS) IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 193 RUSSIA HEMATOPOIETIC MALIGNANCIES IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 194 RUSSIA CANCER RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 195 RUSSIA GENETIC RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 196 RUSSIA INFECTIOUS DISEASE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 197 RUSSIA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 198 RUSSIA RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 199 RUSSIA CLINICAL IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 200 RUSSIA COMPANION DIAGNOSTIC IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 201 RUSSIA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 202 RUSSIA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 203 SWITZERLAND FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 204 SWITZERLAND CONSUMABLES IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 205 SWITZERLAND FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PROBE TYPE, 2021-2030 (USD MILLION)
TABLE 206 SWITZERLAND FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 207 SWITZERLAND FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 208 SWITZERLAND RNA IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 209 SWITZERLAND ACCESSORY KITS & REAGENTS IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 210 SWITZERLAND INSTRUMENTS IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 211 SWITZERLAND FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 212 SWITZERLAND FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 213 SWITZERLAND CANCER RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 214 SWITZERLAND NON-HEMATOPOIETIC MALIGNANCIES (SOLID TUMORS) IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 215 SWITZERLAND HEMATOPOIETIC MALIGNANCIES IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 216 SWITZERLAND CANCER RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 217 SWITZERLAND GENETIC RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 218 SWITZERLAND INFECTIOUS DISEASE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 219 SWITZERLAND FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 220 SWITZERLAND RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 221 SWITZERLAND CLINICAL IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 222 SWITZERLAND COMPANION DIAGNOSTIC IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 223 SWITZERLAND FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 224 SWITZERLAND FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 225 TURKEY FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 226 TURKEY CONSUMABLES IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 227 TURKEY FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PROBE TYPE, 2021-2030 (USD MILLION)
TABLE 228 TURKEY FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 229 TURKEY FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 230 TURKEY RNA IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 231 TURKEY ACCESSORY KITS & REAGENTS IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 232 TURKEY INSTRUMENTS IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 233 TURKEY FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 234 TURKEY FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 235 TURKEY CANCER RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 236 TURKEY NON-HEMATOPOIETIC MALIGNANCIES (SOLID TUMORS) IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 237 TURKEY HEMATOPOIETIC MALIGNANCIES IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 238 TURKEY CANCER RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 239 TURKEY GENETIC RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 240 TURKEY INFECTIOUS DISEASE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 241 TURKEY FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 242 TURKEY RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 243 TURKEY CLINICAL IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 244 TURKEY COMPANION DIAGNOSTIC IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 245 TURKEY FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 246 TURKEY FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 247 BELGIUM FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 248 BELGIUM CONSUMABLES IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 249 BELGIUM FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PROBE TYPE, 2021-2030 (USD MILLION)
TABLE 250 BELGIUM FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 251 BELGIUM FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 252 BELGIUM RNA IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 253 BELGIUM ACCESSORY KITS & REAGENTS IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 254 BELGIUM INSTRUMENTS IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 255 BELGIUM FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 256 BELGIUM FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 257 BELGIUM CANCER RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 258 BELGIUM NON-HEMATOPOIETIC MALIGNANCIES (SOLID TUMORS) IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 259 BELGIUM HEMATOPOIETIC MALIGNANCIES IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 260 BELGIUM CANCER RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 261 BELGIUM GENETIC RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 262 BELGIUM INFECTIOUS DISEASE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 263 BELGIUM FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 264 BELGIUM RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 265 BELGIUM CLINICAL IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 266 BELGIUM COMPANION DIAGNOSTIC IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 267 BELGIUM FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 268 BELGIUM FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 269 NETHERLANDS FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 270 NETHERLANDS CONSUMABLES IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 271 NETHERLANDS FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PROBE TYPE, 2021-2030 (USD MILLION)
TABLE 272 NETHERLANDS FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 273 NETHERLANDS FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 274 NETHERLANDS RNA IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 275 NETHERLANDS ACCESSORY KITS & REAGENTS IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 276 NETHERLANDS INSTRUMENTS IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 277 NETHERLANDS FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 278 NETHERLANDS FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 279 NETHERLANDS CANCER RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 280 NETHERLANDS NON-HEMATOPOIETIC MALIGNANCIES (SOLID TUMORS) IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 281 NETHERLANDS HEMATOPOIETIC MALIGNANCIES IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 282 NETHERLANDS CANCER RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 283 NETHERLANDS GENETIC RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 284 NETHERLANDS INFECTIOUS DISEASE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 285 NETHERLANDS FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 286 NETHERLANDS RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 287 NETHERLANDS CLINICAL IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 288 NETHERLANDS COMPANION DIAGNOSTIC IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 289 NETHERLANDS FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 290 NETHERLANDS FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 291 DENMARK FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 292 DENMARK CONSUMABLES IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 293 DENMARK FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PROBE TYPE, 2021-2030 (USD MILLION)
TABLE 294 DENMARK FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 295 DENMARK FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 296 DENMARK RNA IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 297 DENMARK ACCESSORY KITS & REAGENTS IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 298 DENMARK INSTRUMENTS IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 299 DENMARK FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 300 DENMARK FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 301 DENMARK CANCER RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 302 DENMARK NON-HEMATOPOIETIC MALIGNANCIES (SOLID TUMORS) IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 303 DENMARK HEMATOPOIETIC MALIGNANCIES IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 304 DENMARK CANCER RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 305 DENMARK GENETIC RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 306 DENMARK INFECTIOUS DISEASE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 307 DENMARK FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 308 DENMARK RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 309 DENMARK CLINICAL IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 310 DENMARK COMPANION DIAGNOSTIC IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 311 DENMARK FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 312 DENMARK FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 313 SWEDEN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 314 SWEDEN CONSUMABLES IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 315 SWEDEN FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PROBE TYPE, 2021-2030 (USD MILLION)
TABLE 316 SWEDEN FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 317 SWEDEN FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 318 SWEDEN RNA IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 319 SWEDEN ACCESSORY KITS & REAGENTS IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 320 SWEDEN INSTRUMENTS IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 321 SWEDEN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 322 SWEDEN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 323 SWEDEN CANCER RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 324 SWEDEN NON-HEMATOPOIETIC MALIGNANCIES (SOLID TUMORS) IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 325 SWEDEN HEMATOPOIETIC MALIGNANCIES IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 326 SWEDEN CANCER RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 327 SWEDEN GENETIC RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 328 SWEDEN INFECTIOUS DISEASE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 329 SWEDEN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 330 SWEDEN RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 331 SWEDEN CLINICAL IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 332 SWEDEN COMPANION DIAGNOSTIC IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 333 SWEDEN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 334 SWEDEN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 335 POLAND FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 336 POLAND CONSUMABLES IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 337 POLAND FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PROBE TYPE, 2021-2030 (USD MILLION)
TABLE 338 POLAND FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 339 POLAND FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 340 POLAND RNA IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 341 POLAND ACCESSORY KITS & REAGENTS IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 342 POLAND INSTRUMENTS IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 343 POLAND FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 344 POLAND FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 345 POLAND CANCER RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 346 POLAND NON-HEMATOPOIETIC MALIGNANCIES (SOLID TUMORS) IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 347 POLAND HEMATOPOIETIC MALIGNANCIES IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 348 POLAND CANCER RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 349 POLAND GENETIC RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 350 POLAND INFECTIOUS DISEASE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 351 POLAND FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 352 POLAND RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 353 POLAND CLINICAL IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 354 POLAND COMPANION DIAGNOSTIC IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 355 POLAND FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 356 POLAND FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 357 NORWAY FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 358 NORWAY CONSUMABLES IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 359 NORWAY FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PROBE TYPE, 2021-2030 (USD MILLION)
TABLE 360 NORWAY FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 361 NORWAY FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 362 NORWAY RNA IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 363 NORWAY ACCESSORY KITS & REAGENTS IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 364 NORWAY INSTRUMENTS IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 365 NORWAY FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 366 NORWAY FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 367 NORWAY CANCER RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 368 NORWAY NON-HEMATOPOIETIC MALIGNANCIES (SOLID TUMORS) IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 369 NORWAY HEMATOPOIETIC MALIGNANCIES IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 370 NORWAY CANCER RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 371 NORWAY GENETIC RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 372 NORWAY INFECTIOUS DISEASE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 373 NORWAY FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 374 NORWAY RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 375 NORWAY CLINICAL IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 376 NORWAY COMPANION DIAGNOSTIC IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 377 NORWAY FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 378 NORWAY FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 379 FINLAND FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 380 FINLAND CONSUMABLES IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 381 FINLAND FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PROBE TYPE, 2021-2030 (USD MILLION)
TABLE 382 FINLAND FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 383 FINLAND FISH PROBE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 384 FINLAND RNA IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 385 FINLAND ACCESSORY KITS & REAGENTS IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 386 FINLAND INSTRUMENTS IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 387 FINLAND FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 388 FINLAND FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 389 FINLAND CANCER RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 390 FINLAND NON-HEMATOPOIETIC MALIGNANCIES (SOLID TUMORS) IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 391 FINLAND HEMATOPOIETIC MALIGNANCIES IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 392 FINLAND CANCER RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 393 FINLAND GENETIC RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 394 FINLAND INFECTIOUS DISEASE IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 395 FINLAND FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 396 FINLAND RESEARCH IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 397 FINLAND CLINICAL IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 398 FINLAND COMPANION DIAGNOSTIC IN FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE, 2021-2030 (USD MILLION)
TABLE 399 FINLAND FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 400 FINLAND FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 401 REST OF EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
Liste des figures
FIGURE 1 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: SEGMENTATION
FIGURE 2 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: DATA TRIANGULATION
FIGURE 3 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: DROC ANALYSIS
FIGURE 4 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: EUROPE VS REGIONAL MARKET ANALYSIS
FIGURE 5 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: MARKET APPLICATION COVERAGE GRID
FIGURE 8 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: DBMR MARKET POSITION GRID
FIGURE 9 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: SEGMENTATION
FIGURE 11 THE GROWING BURDEN OF GENETIC DISORDERS AS WELL AS CANCER AND HIGH FUNDING FOR RESEARCH ACTIVITIES IS EXPECTED TO DRIVE THE GROWTH OF THE EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET FROM 2023 TO 2030
FIGURE 12 PRODUCT TYPE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET IN 2023 AND 2030
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET
FIGURE 14 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY PRODUCT TYPE, 2022
FIGURE 15 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY PRODUCT TYPE, 2023-2030 (USD MILLION)
FIGURE 16 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY PRODUCT TYPE, CAGR (2023-2030)
FIGURE 17 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY PRODUCT TYPE, LIFELINE CURVE
FIGURE 18 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY TECHNOLOGY, 2022
FIGURE 19 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY TECHNOLOGY, 2023-2030 (USD MILLION)
FIGURE 20 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY TECHNOLOGY, CAGR (2023-2030)
FIGURE 21 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY TECHNOLOGY, LIFELINE CURVE
FIGURE 22 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY APPLICATION, 2022
FIGURE 23 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY APPLICATION, 2023-2030 (USD MILLION)
FIGURE 24 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY APPLICATION, CAGR (2023-2030)
FIGURE 25 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 26 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY USAGE, 2022
FIGURE 27 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY USAGE, 2023-2030 (USD MILLION)
FIGURE 28 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY USAGE, CAGR (2023-2030)
FIGURE 29 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY USAGE, LIFELINE CURVE
FIGURE 30 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY END USER, 2022
FIGURE 31 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY END USER, 2023-2030 (USD MILLION)
FIGURE 32 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY END USER, CAGR (2023-2030)
FIGURE 33 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY END USER, LIFELINE CURVE
FIGURE 34 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY DISTRIBUTION CHANNEL, 2022
FIGURE 35 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION)
FIGURE 36 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030)
FIGURE 37 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 38 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: SNAPSHOT (2022)
FIGURE 39 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY COUNTRY (2022)
FIGURE 40 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY COUNTRY (2023 & 2030)
FIGURE 41 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: BY COUNTRY (2022 & 2030)
FIGURE 42 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: PRODUCT TYPE (2023-2030)
FIGURE 43 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: COMPANY SHARE 2022 (%)
Méthodologie de recherche
La collecte de données et l'analyse de l'année de base sont effectuées à l'aide de modules de collecte de données avec des échantillons de grande taille. L'étape consiste à obtenir des informations sur le marché ou des données connexes via diverses sources et stratégies. Elle comprend l'examen et la planification à l'avance de toutes les données acquises dans le passé. Elle englobe également l'examen des incohérences d'informations observées dans différentes sources d'informations. Les données de marché sont analysées et estimées à l'aide de modèles statistiques et cohérents de marché. De plus, l'analyse des parts de marché et l'analyse des tendances clés sont les principaux facteurs de succès du rapport de marché. Pour en savoir plus, veuillez demander un appel d'analyste ou déposer votre demande.
La méthodologie de recherche clé utilisée par l'équipe de recherche DBMR est la triangulation des données qui implique l'exploration de données, l'analyse de l'impact des variables de données sur le marché et la validation primaire (expert du secteur). Les modèles de données incluent la grille de positionnement des fournisseurs, l'analyse de la chronologie du marché, l'aperçu et le guide du marché, la grille de positionnement des entreprises, l'analyse des brevets, l'analyse des prix, l'analyse des parts de marché des entreprises, les normes de mesure, l'analyse globale par rapport à l'analyse régionale et des parts des fournisseurs. Pour en savoir plus sur la méthodologie de recherche, envoyez une demande pour parler à nos experts du secteur.
Personnalisation disponible
Data Bridge Market Research est un leader de la recherche formative avancée. Nous sommes fiers de fournir à nos clients existants et nouveaux des données et des analyses qui correspondent à leurs objectifs. Le rapport peut être personnalisé pour inclure une analyse des tendances des prix des marques cibles, une compréhension du marché pour d'autres pays (demandez la liste des pays), des données sur les résultats des essais cliniques, une revue de la littérature, une analyse du marché des produits remis à neuf et de la base de produits. L'analyse du marché des concurrents cibles peut être analysée à partir d'une analyse basée sur la technologie jusqu'à des stratégies de portefeuille de marché. Nous pouvons ajouter autant de concurrents que vous le souhaitez, dans le format et le style de données que vous recherchez. Notre équipe d'analystes peut également vous fournir des données sous forme de fichiers Excel bruts, de tableaux croisés dynamiques (Fact book) ou peut vous aider à créer des présentations à partir des ensembles de données disponibles dans le rapport.
